Amantadine/Oseltamivir/Ribavirin
- Generic Name
- Amantadine/Oseltamivir/Ribavirin
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT00979251
- Locations
- 🇸🇬
Adamas Investigational Site, Singapore, Singapore
🇦🇺Adamas Investigative Site, Parkville, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath